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Abstract: BACKGROUND Gout is the most common form of inflammatory arthritis worldwide and
its prevalence is rising. In Switzerland, there are no data available on the characteristics and treat-
ment of gout patients. In this study, we aimed to describe numbers of patients affected by gout and
hyperuricaemia and unveil approaches Swiss primary care physicians (PCPs) use for the management.
METHODS This was a retrospective observational study using electronic medical routine nbsp;data pro-
vided from 242 Swiss PCPs. Included were all their patients receiving urate-lowering therapy (ULT), with
a diagnostic code for gout or who had a serum uric acid (SUA) measurement. According to their disease
status, patients were classified into four subgroups (normal urate, hyperuricaemia, untreated gout, treated
gout). For treatment analysis, patients with SUA measurements before and after ULT initiation were in-
cluded. Comorbidities and risk factors for secondary causes relevant in the context of gout were collected.
Outcomes were prevalence of gout and hyperuricaemia, characteristics of patients according to subgroup,
number of SUA measurements, levels of SUA and patients who reached the treatment goal of a SUA level
lt;360 micro;mol/l. RESULTS We assessed 15,808 patients and classified them into the subgroups. This
yielded a prevalence of 1.0% for gout and 1.2% for hyperuricaemia. 2642 patients were diagnosed with
gout of whom 2420 (91.6%) received a ULT. Overall; 41.3% of patients with a gout treatment had at least
one SUA measurement; 15.0% of patients with treated gout had a record of SUA measurements before
and after ULT initiation; and 57.5% reached the treatment goal of lt;360 micro;mol/l after allopurinol
treatment. CONCLUSION Swiss gout patients received comprehensive treatment, which is reflected in
a high number of patients treated with ULT, laboratory tests per person and a high treatment success
rate, although there is no systematic approach to the treatment of gout.
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Summary
BACKGROUND: Gout is the most common form of inflam-
matory arthritis worldwide and its prevalence is rising. In
Switzerland, there are no data available on the charac-
teristics and treatment of gout patients. In this study, we
aimed to describe numbers of patients affected by gout
and hyperuricaemia and unveil approaches Swiss primary
care physicians (PCPs) use for the management.
METHODS: This was a retrospective observational study
using electronic medical routine data provided from 242
Swiss PCPs. Included were all their patients receiving
urate-lowering therapy (ULT), with a diagnostic code for
gout or who had a serum uric acid (SUA) measurement.
According to their disease status, patients were classified
into four subgroups (normal urate, hyperuricaemia, un-
treated gout, treated gout). For treatment analysis, pa-
tients with SUA measurements before and after ULT ini-
tiation were included. Comorbidities and risk factors for
secondary causes relevant in the context of gout were col-
lected. Outcomes were prevalence of gout and hyperuri-
caemia, characteristics of patients according to subgroup,
number of SUA measurements, levels of SUA and pa-
tients who reached the treatment goal of a SUA level <360
µmol/l.
RESULTS: We assessed 15,808 patients and classified
them into the subgroups. This yielded a prevalence of
1.0% for gout and 1.2% for hyperuricaemia. 2642 patients
were diagnosed with gout of whom 2420 (91.6%) received
a ULT. Overall; 41.3% of patients with a gout treatment
had at least one SUA measurement; 15.0% of patients
with treated gout had a record of SUA measurements be-
fore and after ULT initiation; and 57.5% reached the treat-
ment goal of <360 µmol/l after allopurinol treatment.
CONCLUSION: Swiss gout patients received comprehen-
sive treatment, which is reflected in a high number of pa-
tients treated with ULT, laboratory tests per person and a
high treatment success rate, although there is no system-
atic approach to the treatment of gout.
Keywords: gout, hyperuricaemia, urate lowering therapy,
variety of care, electronic medical routine data
Introduction
Gout is the most common form of inflammatory arthritis
worldwide and its prevalence is rising. The highest preva-
lence has been reported in occidental countries and among
oceanic populations, affecting up to 7.6% of the popula-
tion, which is a doubling in occidental countries in the
last 15 years [1–7]. Similar in its clinical appearance to
gout, hyperuricaemia is reported to be rising with a report-
ed prevalence of up to 21.4% [4–6, 8]. In contrast to gout,
which is diagnosed clinically, the diagnosis of hyperuri-
caemia is solely defined by serum uric acid (SUA) levels
above 400 µmol/l (6.8 mg/dl) [7, 9–11].
There is international evidence that the management of
these non-communicable entities varies widely. Previous
studies investigating primary care populations in different
occidental countries reported that 9–74% of all patients di-
agnosed with gout had SUA measurements, and 40–84.5%
of all patients were treated with urate-lowering therapy
(ULT) [3, 12–17]. Among treated patients, 21–50%
reached the treatment target of <360 µmol/l (<6 mg/dl)
recommended in most guidelines [18–20]. A recent Swiss
guideline is in concordance with the international guide-
lines and recommends the treatment target of <360 µmol/
l for gout patients, whereas it is not recommended to treat
hyperuricaemia [21]. However, data on prevalence and the
actual management of gout and hyperuricaemia in primary
care is lacking for Switzerland.
Therefore, the aims of this study were:
– To investigate numbers and prevalence of patients af-
fected by gout or hyperuricaemia to describe population
characteristics and to assess differences in subpopula-
tions
– To describe approaches Swiss primary care physicians
(PCPs) used for the management of gout and to assess
if the treatment goal (SUA level ≤ 360 µmol/l) was
reached and which factors were associated with doing
so.
Methods
Study design and setting
We conducted a retrospective observational database
analysis based on the FIRE (family medicine International
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Classification of Primary Care [ICPC] research using elec-
tronic medical records) database, which was established in
2009 [22]. The FIRE database is a continuous collection
of structured medical routine data from Swiss primary care
practices. Until August 2019, more than 540 PCPs (ap-
proximately 10% of general practitioners working in the
German-speaking region of Switzerland [23]) from more
than 180 practices participated on a voluntary basis. This
resulted in records from more 600,000 patients and more
than 7 million consultations. In brief, the database covers
patient demographics, vital signs, laboratory data, pre-
scribed medication according to anatomical therapeutic
chemical (ATC) coding and diagnoses based on ICPC Ver-
sion 2 [24, 25]. For this analysis, data from 1 January 2009
to 31 August 2018 were included. According to the Local
Ethics Committee of the Canton of Zurich, the project did
not fall under the scope of the law on human research [26]
and therefore no ethical consent was necessary (BASEC-
Nr: Req-2017-00797).
Eligibility and inclusion criteria
Practices were eligible if they provided SUA measure-
ments for FIRE. Within these practices, all patients alive
and aged between 18 and 90 were included if one of the
following criteria were fulfilled: (a) at least one prescrip-
tion of ULT (ATC code M04); (b) ICPC code of gout
(T92); (c) at least one SUA measurement.
Patient subgroups
The following subgroups were defined for further assess-
ments of patient characteristic: normal urate (first SUA
level <400 µmol/l, no ULT, no ICPC T92), hyperuricaemia
(first SUA level >400 µmol/l, no ULT, no ICPC T92), un-
treated gout (ICPC T92, no ULT) and treated gout (ICPC
T92, use of a ULT). For the analysis of the disease manage-
ment, treated gout patients with available SUA measure-
ments before and after treatment initiation were analysed
according to their received treatment (allopurinol: ATC
M04AA01; febuxostat: ATC M04AA03) and sex. The pa-
tient selection process is visualised in the study flowchart
(fig. 1).
Database query and variables
From the FIRE database, we retrieved the following in-
formation at PCP level: age, sex, practice location (urban
vs rural [27]) and practice type (single vs group practice).
At patient level we retrieved: (a) demographic data (age,
sex and body mass index [BMI]); (b) treatment data (num-
ber of SUA measurements, level of SUA measurements,
type of medication); (c) information about comorbidities
(alcohol abuse, obesity, hypertension, diabetes mellitus,
dyslipidaemia, cardiovascular disease); and risk factors in-
fluencing SUA levels by increasing SUA production (pso-
riasis, high cell turnover diseases, cytotoxic chemothera-
peutics) or by decreasing excretion (chronic kidney disease
[CKD] stage 3a and higher, congestive heart failure, diuret-
ics, laxatives) [28, 29]. Comorbidities and risk factors were
defined using ICPC codes, laboratory measurements and
ATC-codes (for detailed identification schemes see supple-
mentary tables S1 and S2 in appendix 1) [30, 31].
Statistical analysis
We described patient level categorical data as numbers
and proportions (n, %) and patient level continuous data
as means and standard deviations (SDs). The percentage
of missing observations was reported when necessary. To
compare patient characteristics between patient subgroups,
we used the chi-squared test for categorical variables and
the analysis of variance (ANOVA) test for continuous vari-
ables. When testing difference in means or proportions be-
tween two groups, we reported results as 95% confidence
intervals (CIs). A logistic multivariable mixed model, cor-
recting for sex and repeated measurements (nested random
effects: PCPs/patients) was used to examine treatment suc-
cess. We specified the model as follows:
SUA level ≤360 µmol/l ~ fixed effects (X) + random ef-
fects of intercept (PCPs/patients)
where X = treatment indicator, sex.
We represented the results of the model as odds ratios
(ORs) with 95% CI. The observations with missing values
were excluded for regression analysis, but still included in
the descriptive analysis. A p-value ≤0.05 was considered
statistically significant. All statistical analyses were carried
out using the R statistical package [32].
Results
Population characteristics
Within the FIRE network, 97 distinct practices with 242
PCPs covered 15,808 eligible patients (fig. 1). The PCPs’
mean age was 51.7 years (SD 10.4), 148 (61.2%) were
male, 219 (90.5%) worked in a double or group practice
and 130 (53.7%) practiced in an urban area. At the patient
level, 15,808 patients met the inclusion criteria. Their
mean age was 58.9 years (SD 16.2) and 8,840 (55.9%)
were male; 49.1% (n = 7764) of the patient population
had at least two comorbidities of which dyslipidaemia (n =
10,569, 66.9%), hypertension (n = 8990, 56.9%) and dia-
betes (n = 1704, 10.8%) were the most prevalent. We iden-
tified 4672 (29.6%) patients having risk factors for sec-
ondary causes of which the three most common were the
use of diuretics (n = 3266, 20.7%), CKD stage 3a or high-
er (n = 2066, 13.1%) and the use of laxatives (n = 1187,
7.5%).
Subgroup classification revealed that 5773 (36.5%) of all
eligible patients were affected by hyperuricaemia or gout,
which resulted in a prevalence of 1.0% for gout and 1.2%
for hyperuricaemia. All patient characteristics differed sta-




Overall, 22,169 SUA measurements were available. The
mean number of SUA measurements per patient was 1.4
(SD 1.3) and mean SUA level was 339.4 µmol/l (SD 98.0).
The SUA level was significantly higher among men (376.7
µmol/l, SD 89.6) than women (296.3 µmol/l, SD 89.3)
with a 95% CI for the difference of −83.3 to −77.4 µmol/
l. Moreover, SUA level rose with CKD grade. The number
and the level of SUA measurements differed significantly
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between patient subgroups (table 1). Among the gout pa-
tients (treated and untreated), 1090 patients (41.3%) had at
least one SUA measurement. Of the treated gout patients
364 (15.0%) had at least one SUA measurement before
and after ULT initiation and were therefore eligible for the
treatment effect analysis.
Treatment
Of all patients affected with gout, 2,420 (91.6%) were
treated. The proportion of treated patients did not differ
significantly between the sexes (1832, 91.4% of men and
588, 92.2% of women, p = 0.610 with a 95% CI for the
difference of –0.02 to 0.03). Treatment with allopurinol
led to a statistically significant average drop in SUA level
of 67 µmol/l (95% CI 53.8 to 79.5) (table 2). The drop
was 77 µmol/l in women (95% CI 49.5 to 104.3µmol/l)
and 60 µmol/l in men (95% CI 46.2 to 75.0 µmol/l). The
treatment goal of SUA ≤360 µmol/l was reached by 199
patients (57.5%), 69 female patients (68.3% of all treated
women), and 130 male patients (53.1% of all treated men).
The OR for achieving the treatment goal with treatment
was 4.34, (p <0.001, 95% CI 3.15 to 6.08). Female patients
were more likely to achieve the treatment goal: OR 2.36 (p
<0.001, 95% CI 1.53 to 3.69).
Only 28 patients in our sample had SUA measurements
before and after treatment initiation with febuxostat (table
3). Febuxostat led to a drop in SUA level, of 71 µmol/
Figure 1: Flow chart of the study design and inclusion/exclusion criteria including number and proportions of patients. FIRE = family medicine
ICPC Research using electronic medical records; ICPC = international classification of primary care; PCP = primary care physician; SUA =
serum uric acid; ULT: urate-lowering therapy
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l (p <0.001, 95% CI −3.2 to 143.5). The mean drop was
112 µmol/l, (95% CI 64.8 to 157.7 µmol/l) in men and 36
µmol/l, (95% CI −138.7 to 211.9) in women. Treatment
success was reached in 67.9% of the 28 treated patients (in
men 66.7%, in women 71.4%).
Treatment patterns
To investigate the treatment pattern of PCPs, we assessed
SUA measurements before and after initiating ULT. Figure
2 displays a random sample of patients treated with ULT.
As can be seen, SUA measurements before and after ULT
initiation show a high variation in absolute numbers as
well as in time intervals before and after treatment started.
Discussion
Our data analysis of Swiss primary care patients yielded
a low prevalence of gout and hyperuricaemia. However,
within all those eligible, 35% of patients were affected
by gout or hyperuricaemia and more than 50% of those
affected by gout had risk factors for secondary causes.
The majority (91.6%) of patients affected by gout received
treatment, of whom the vast majority (97.4%) received al-
lopurinol. The number of SUA measurements among indi-
Table 1: Patient characteristics according to defined subgroups.
Normal urate Hyperuricaemia Untreated gout Treated gout p-value
Patient characteristics Number of patients 10,035 3131 222 2420
Age (years), mean (SD) 55.5 (16.0) 62.3 (15.6) 63.4 (15.6) 68.1 (13.0) <0.001
Sex male, n (%) 4411 (44.0)) 2425 (77.5) 172 (77.5) 1832 (75.7) <0.001
BMI class,
n (%)
Normal weight 17 (7.7) 236 (7.5) 69 (2.9) 1596 (15.9) <0.001
Obese 50 (22.5) 485 (15.5) 302 (12.5) 748 (7.5)
Overweight 44 (19.8) 542 (17.3) 263 (10.9) 1475 (14.7)
Underweight 0 (0.0) 12 (0.4) 9 (0.4) 286 (2.9)
Number of chronic diseases, mean
(SD)
1.33 (0.95) 1.75 (1.01) 2.08 (1.53) 2.04 (1.21) <0.001
Risk factors and comor-
bidities, n (%)
Dyslipidaemia 6901 (68.8) 2284 (72.9) 117 (52.7) 1267 (52.4) <0.001
Hypertension 4733 (47.2) 2111 (67.4) 150 (67.6) 1988 (82.4) <0.001
Diabetes 662 (6.6) 411 (13.1) 47 (21.1) 584 (24.1) <0.001
Cardiovascular disease 270 (2.7) 191 (6.1) 48 (21.6) 200 (8.3) <0.001
Risk factors 1874 (18.7) 1100 (35.1) 111 (50) 1587 (65.6) <0.001
Diuretics 1092 (10.9) 891 (28.5) 66 (29.7) 1217 (50.3) <0.001
CKD 684 (6.8) 751 (23.9) 49 (22.1) 582 (24.0) <0.001
Laxatives 640 (6.4) 240 (7.7) 19 (8.6) 288 (11.9) <0.001
SUA measurements,
mean (SD)
SUA measurements 1.37 (0.91) 1.79 (1.46) 0.62 (0.91) 1.10 (2.12) <0.001
SUA level* 293.5 (60.3) 458.1 (67.9) 439.3 (112.5) 419.0 (111.6) <0.001
Treatment, n (%) Allopurinol 0 (0.0) 0 (0.0) 0 (0.0) 2,357 (97.4)
Febuxostat 0 (0.0) 0 (0.0) 0 (0.0) 91 (3.8)
Probenecid 0 (0.0) 0 (0.0) 0 (0.0) 13 (0.5)
BMI = body mass index; CKD= chronic kidney disease 3b or higher; SD = standard deviation; SUA = serum uric acid * Percentages were calculated including missing values.
Missing were: BMI 61.2%, SUA levels 9.8%. Reported p-values result from chi-square test (categorical variables) or ANOVA test (continuous variables). BMI classes are: under-
weight = BMI <20 kg/m2; normal weigh = BMI ≥20 and <25 kg/m2; overweight = BMI ≥25 and < 30 kg/m2; obese = BMI ≥30 kg/m2





SUA levels (µmol/l) SUA ≤360 µmol
(%)Mean SD
Total Before 346 581 480 127 21.7%
After 346 933 413 119 57.5%
Male Before 245 434 485 120.7 19.6%
After 245 651 425 115.2 53.1%
Female Before 101 147 463 143.4 26.7%
After 101 282 386 123.2 68.3%
SD = standard deviation; SUA = serum uric acid





SUA levels (µmol/l) SUA ≤360 µmol
(%)Mean SD
Total Before 28 69 525 146.6 14.3%
After 28 85 454 300.6 67.9%
Male Before 21 50 504 111.7 9.5%
After 21 50 392 122.3 66.7%
Female Before 7 19 579 206.9 28.6%
After 7 35 543 433.6 71.4%
SD = standard deviation; SUA = serum uric acid
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vidual patients varied widely, indicating that most PCPs do
not have a systematic approach to hyperuricaemia or gout.
In recent studies, the prevalence of gout varied widely and
was conflated to the range of 1–4% by Kuo et al. 2015.
In studies reporting the prevalence of both, the prevalence
of hyperuricaemia was three to five times higher than the
prevalence of gout [4–6]. Our study reported a gout preva-
lence on the lower end of the range found in literature. In-
terestingly, survey data resulted generally in a rather higher
gout prevalence than results from administrative or patient
record data, which supports the validity of our data for gout
[3, 4, 6, 12]. In contrast, the prevalence of hyperuricaemia
reported in our study is much lower and suggests a large
underestimation in our data [33]. This is mainly explained
by the absence of a systematic screening within our “real
world” primary care study population – which is not rec-
ommended by any guideline and benefit of which has not
yet been studied [34, 35]. With regard to comorbidities and
risk factors for secondary gout and hyperuricaemia, our re-
sults are comparable to the prevalence and proportions re-
ported in previous studies [3, 6, 16].
Treatment rate of gout patients with ULT ranged among
the highest ever reported; similarly high treatment rates
were only documented in Germany (84.5%) and France
(83%) [3, 14], where for many other countries, for instance
the United Kingdom, the United States or Australia, treat-
ment rates of 34%, 40% or 57% were reported [12, 15,
17, 36]. Moreover, besides the treatment rate, treatment
success in patients who recorded a SUA before and after
treatment initiation with allopurinol was achieved in 36%
of cases, and was among the highest reported rates so far
in primary care populations (21–40.9%) [12, 14, 15, 17,
36]. Treatment success in patients receiving with febuxo-
stat was even higher, but owing to the small sample size,
the result might not be very robust. The regression analysis
revealed that female patients were more likely to achieve
the treatment goal then male patients. This might be par-
tially because female patients started with a lower SUA
level than male patients, but it is also known that female
patients are generally more closely monitored than male
patients [37]. In general, the high treatment success rates in
our sample might be influenced by the subgroup identifi-
cation, which selected the patients most closely monitored.
The high variability in the number of SUA measurements
among individual patients and treatment patterns is in line
with previous observational studies (9–79% of those diag-
nosed with gout had at least one SUA measurement) [3,
12, 36]. This high variability persisted, regardless of sex,
treatment status and after correction for PCP as a cluster.
Even among the subgroup of patients receiving ULT, a uni-
form and systematic approach via frequent SUA measure-
ments, reflecting monitoring as it is established in many
other chronic diseases, could not be detected. Obviously,
gout does not receive the same awareness as, for instance,
diabetes, and considerable gaps in disease knowledge and
education among PCPs and patients exist [38].
Strengths and limitations
There are a number of limitations that should be consid-
ered when interpreting the results of our study. An impor-
tant limitation of this study is missing information from
electronic medical record as we could only assess struc-
tured data entries. Data entries such as free text diagnoses
are lost. We would like to point out that we cannot exclude
the possibility of misclassification within different patient
subgroups as the definition of untreated gout was based
solely on ICPC2-codes, which were not systematically
provided by all PCPs. Therefore, the number of untreated
gout cases might be underestimated, which also influences
the reported prevalence for gout. The reported prevalence
for hyperuricaemia must be considered with caution, as
systematic hyperuricaemia screening is lacking in Swiss
Figure 2: The variation of SUA measurements among a randomly chosen sample of treated patients (men and women). Blue circles define
SUA level measurement before treatment was started. Red circles define SUA level measurements after treatment was started. The zero-
point on the timeline is defined as the day when treatment was started. SUA = serum uric acid
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primary care and only patients who had a SUA measure-
ment at their PCP’s practice could be covered. Further, in-
formation on the dosage was not systematically available
within our data and hence we could not address treatment
aspects concerning the dosage.
On the other hand, our study has some important strengths.
First, our sample of PCPs is representative of the Swiss
PCP community in terms of gender, but slightly over-rep-
resents younger PCPs, PCPs working in group practices in
urban settings [23]. Further, the validity of laboratory data
is high since they are directly imported from the laboratory
machines. Similarly, prescribed drugs are digitally record-
ed and effectively reflect PCPs’ real-life treatment of gout.
To our knowledge, we are the first to examine the situa-
tion of gout and hyperuricaemia in Switzerland and how
patients are treated in the Swiss primary care setting.
Conclusion
Swiss gout patients received comprehensive treatment,
which is reflected in a high number of patients treated with
ULT, laboratory tests per person and a high treatment suc-
cess rate, although there is no systematic approach to the
treatment of gout. As gout and hyperuricaemia are among
the fastest rising non-communicable diseases, affecting the
quality of life of patients tremendously, awareness and
knowledge of the need for a systematic approach to patient
treatment should be increased.
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Appendix 1 Supplementary tables
Table S1: Details of definitions to identify comorbidities.
Alcohol abuse ICPC-2 = 'P15|P16' OR ATC = 'N07BB01'
Obesity ICPC-2 = T83 OR BMI ≥25 and <30 THEN 'overweight'
ICPC-2 = T82 OR BMI ≥30 THEN 'obese'
Hypertension ICPC-2 = 'K8[5–7]
OR ATC = 'C02|C03A|C03EA01|C07|C08|C09A|C09B|C09C|C09D'
OR ≥2 prescriptions in ≥6 months OR BDSYST ≥140 (at least twice)
Diabetes ICPC-2 = (T89, T90) OR (ATC IN ('A10[ABX]' OR HbA1c >6.5%
Dyslipidaemia ICPC-2 = T93 OR (ATC = C10A AND ≥2 prescriptions in ≥6 months)
OR triglyceride >1.7 mmol/l OR total-cholesterol >4.9 mmol/l
OR LDL-cholesterol >3 mmol/l OR (sex = 'female' AND HDL-cholesterol ≤1.2 mmol/l) OR (sex = 'male' AND HDL-cholesterol ≤1
mmol/l)
Cardiovascular diseases ICPC-2 = 'K74|K75|K76|K77|K78|K79| F83|K89|K90|K91|K92'
Table S2: Details of definitions to identify risk factors.
Increasing serum uric acid production
Psoriasis ICPC-2 = 'S91'
Myeloma, lymphoma ICPC-2 = 'B7[2–4]'
Solid tumours ICPC-2 = A79 | D7[4–8] | L71 | N74 | R8[4, 5] | X7[5–7] | Y77'
Cytotoxic therapy ATC = 'L04 | L01D | A12AA05 | C04AC | V06DC02 | C10AD | C10BA01 | C04AC01 | C10AD02 | C10AD52 | G04CB | G03FA05 |
G03BA02 | G03EK01 | G03EA01 | G03BA03 | G03EA02 | A12AA06 | B05CA08 | D08AA01 | A12CC06 | B05XA15'
Decreasing serum uric acid excretion
Chronic kidney disease stage 3a and high-
er
GFR (CKD-EPI) =< 60 AND before OR after 30 days of inclusion
Congestive heart failure ICPC-2 = 'K77'
Diuretics ATC = C03 | C02L | C07C | C07D | C08G | C02LA | C02LB | C02LC | C02LE | C02LF | C02LG | C02LK | C02LL | C02LN | C02LX
| C07CA | C07CB | C07CG | C07DA | C07DB | C08GA | C09BA | C09DA | C08GA02 | C07CB03C07CB53 | C07DB01 | C09DA09
| C09BA07 | C02LA07 | C07CA17 | C09DA06 | C09BA01 | C09BA08 | C02LC01 | C02LC51 | C02LA50 | C09BA12 | C02LA03 |
C02LG01 | C02LG51 | C09BA02 | C09DA02 | C09DA10 | C09BA09 | C02LF01 | C02LG02 | C09DA04 | C07CG01 | C09BA03 |
C09DA01 | C02LA04 | C02LB01 | C07CB02 | C09BA13 | C02LC05 | C08GA01 | C07CA02 | C02LL01 | C07CA23 | C09BA04 |
C02LG03 | C02LG73 | C02LX01 | C07CA03 | C02LE01 | C09BA06 | C09BA05 | C02LA08 | C02LA02 | C02LA52 | C02LA01 |
C02LA51 | C02LA71 | C02LA09 | C09DA07 | C07DA06 | C09DA03 | C02LK01 | C09BA15
Laxatives ATC = 'A06AD'
Ethambutol, pyrazinamide ATC = 'J04AK02|J04AK01'
Aspirin ATC = 'B01AC06'
Levodopa ATC = 'N04BA'
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